Objectives
We recently assessed the performance of commercial assays in detecting herpes simplex virus type 1 (HSV-1) antibodies in a composite population derived from different Middle Eastern and North African (MENA) nationalities [18] . Though several studies have used tests that are not well characterized to estimate HSV-2 prevalence in MENA populations [19] , no study, to our knowledge, has investigated the diagnostic performance of commercial tests in detecting HSV-2 antibodies in this region. Our aim in this study was to use a similar methodology to that described previously for HSV-1 test evaluation [18] , to compare the diagnostic performance of four widely available commercial tests in detecting HSV-2 antibodies. We further aimed to assess the diagnostic performance of two enzyme-linked immunosorbent assays (ELISA) kits against two HSV-2 immunoblot (IB) or IB/WB assays, with the latter assays treated here as reference assays, to consider their possible use in confirming ELISA results. Accordingly, we provide, to our knowledge for the first time, an assessment of well-characterized, widely available HSV-2 type-specific commercial tests in detecting HSV-2 antibodies within a MENA population.
Study design
Study methodology followed closely that developed recently to assess the performance evaluation of commercial tests in detecting HSV-1 antibodies, as described previously by Aldisi et al. 2018 [18] .
Study population
The study sample set was selected from a total of 4525 blood specimens previously drawn for other studies [20] [21] [22] [23] , between June 2013 and June 2016. Specimens were anonymously drawn from voluntary blood donors at Hamad Medical Corporation, the national healthcare organization in Qatar, and serum aliquots stored, frozen. These donors were men, ≥18 years of age (median of 37.0 years and range of 19.0-63.0 years), and were Qatari citizens or expatriates from different countries of the MENA region, who were mostly recent residents in Qatar [24, 25] .
Twenty frozen, archived sera were randomly selected from donors from each of ten countries (Egypt, Iran, Jordan, Lebanon, Pakistan, Palestine, Qatar, Sudan, Syria, and Yemen), to provide a total of 200 specimens-a sample broadly representative of the overall MENA population. Informed by previous studies in the literature [16, 26, 27] , this sample size was deemed feasible and reasonable to estimate comparison metrics with acceptable confidence interval width, in particular Cohen's Kappa statistic [28] . Of notice that HSV-2 seroprevalence is similar across these national populations [25] . The research protocol met the ethical standards and was approved by the research committees in Qatar University, Hamad Medical Corporation, and Weill Cornell Medicine-Qatar.
Antibody detection
Four HSV-2 type-specific antibody tests were used. Two of these contains purified type-specific proteins for HSV-2 gG2 and HSV-1 gG-1, as well as a common protein mixture [31, 32] . The Euroline-WB assay included strips of HSV-1 proteins that had been denatured, electrophoretically separated and subsequently transferred to paper strips ("WB") [33] . Glycoprotein gG-2 was then applied to a separate area on the Western blots, for the HSV-2 IB portion of the test [33] . Laboratory testing and interpretation of results were conducted following the manufacturers' instructions. For both ELISA assays, the results were obtained by photometric measurements of the reaction at a wavelength of 450 nm. The change in the color intensity after adding the stop reagent was measured by its optical density using Epoch 2 microplate spectrophotometer (BioTek instruments, U.S.A). Then, the index values were calculated by dividing the optical densities of the controls or specimens by the average of the cut-off calibrator absorbance values. For HerpeSelect ® 2 ELISA, sera with index values of < 0.90 were considered anti-HSV-2 negative, > 1.10 were considered anti-HSV-2 positive, and inclusive values between 0.90 and 1.10 were considered anti-HSV-2 equivocal [29] . For Euroimmun Anti-HSV-2 ELISA, sera with optical density index values < 0.80 were considered anti-HSV-2 negative, ≥1.10 were considered anti-HSV-2 positive, and between 0.80 and 1.10 were considered anti-HSV-2 equivocal
For HerpeSelect ® IB, the produced band intensity of the tested sera was evaluated visually against bands produced from the positive and negative controls [31] . Each resulted band on the immunoblot strips was compared relative to the provided reading control band, which is a gG-2 band on the cutoff/positive control strip. Bands darker than the reading control band were considered positive while lighter bands were considered negative. For Euroline-WB, results were assessed using a EurolineScan software scanner [33] . The software was used to scan and digitally evaluate the strips according to the presence and intensity of clear recognizable bands. Wet blot strips were placed on a green sheet of paper (for maximum resolution) and scanned using a scanner connected to the software. The EUROLineScan is able to measure band intensities, and according to the number of units each band produces, it is categorized into either positive, negative, or borderline. Negative results were ≤12 units, borderline 13-20 units, and positive results correlated with ≥20 units.
Statistical analysis
The four assays were compared to each other by cross tabulating the results to provide six combinations of contingency tables. Equivocal outcomes were not included in analysis. The following comparison metrics were calculated: positive, negative, and overall percent agreements and Cohen's kappa statistic. The latter metric provides a robust and standard statistical measure of the degree of agreement (beyond chance) between any two diagnostic methods [28] . With a range of values between 0 and 1, Cohen's kappa statistic ≥0.75 indicates excellent agreement, 0.40-0.75 indicates fair to good agreement, and < 0.40 indicates poor agreement [18, 28] .
Treating each of HerpeSelect ® IB and Euroline-WB as a reference standard for assessing the performance of the two ELISA kits, the following additional comparison metrics were calculated: sensitivity, specificity, and positive and negative predictive values. Statistical significance was assumed at 5%, and a 95% confidence interval (CI) was estimated for each metric. All calculations were performed using Microsoft Excel 2016.
Results
All 200 MENA blood specimens were tested for HSV-2 antibodies using HerpeSelect ® 2 ELISA, Euroimmun Anti-HSV-2 ELISA, and Testing identified 27 specimens with at least one of the four assays detecting positive or equivocal HSV-2 antibodies (Table 1) . Testing identified a total of ten specimens with an equivocal outcome (three by Euroimmun Anti-HSV-2 ELISA, one by Euroline-WB, six by HerpeSelect ® IB, and none by more than one test). A total of 187 specimens had no equivocal results on any of the diagnostic assays. Among these 187 sera, eight (4.3%) specimens were tested positive for HSV-2 antibodies by only one of the four assays, four (2.1%) specimens were positive in combinations of two assays, none were positive in combinations of three assays, and five (2.7%) were positive and 170 (90.9%) were negative in all four assays. Of note that one specimen was tested positive by three diagnostic assays, but the remaining fourth assay reported an equivocal result. The six cross-tabulations performed comparing the four assays are presented in Fig. 1 . Results of the concordance assessment between the four diagnostic assays are reported in 
Discussion
Four widely available commercial ELISA and IB/WB assays were examined for the performance of detecting HSV-2 antibodies in a composite population from the MENA region. Each of these tests has been compared (in existing literature) with accepted gold standard tests for sensitivity and specificity; usually, but not exclusively, among populations with relatively high HSV-2 seroprevalence [12] [13] [14] [15] [16] 26, 32, 34] . Compared to each other, the four tests demonstrated fair to good agreement with a Cohen's kappa statistic of about 0.6 across the six comparisons. While the overall and negative percent agreements were high (> 95%), the positive percent agreement was imperfect at about 60%.
Compared to the two IB/WB assays, the specificity of the two ELISA kits was high (> 98%), but the sensitivity was low at about 60%-contrary to what one would have desired for such less expensive and automated ELISA tests. While these results support the comparable performance and utility of these four assays, they also affirm known challenges with commercial assays in the reliable detection of HSV-2 antibodies, such as in terms of the positive predictive value [13, 14, 16, [35] [36] [37] [38] , in both low HSV-2 prevalence areas like the MENA region [3, 19, 25, 39] , and high HSV-2 prevalence populations elsewhere [3, [13] [14] [15] [16] 39] .
The results further highlight that the context in which a study is done; for example a low versus high HSV-2 prevalence setting, can affect considerably the interpretation of the results of the serology testing. Indeed, for clinical diagnosis, the results indicate that the usual confirmatory algorithm of inexpensive fast high sensitivity/low specificity test to screen, followed by more expensive, more time intensive confirmatory test to rule out false positives [35, 40] , does not appear to work well in this studied low-seroprevalence MENA population.
Given existing evidence for variation in anti-HSV-2 assay performance by geographic location of the tested population [13] [14] [15] [16] , our results provide useful data, for the first time, for the performance of these assays in a MENA population. Given the finding of unexpected (apparently) low sensitivity for the two ELISA tests, our data demonstrate the need to develop a multiple test algorithms in identifying HSV-2 antibody positivity, particularly in such low HSV-2 seroprevalence populations, as suggested earlier [16, 26, 37] . The findings suggest also that caution should be used in interpreting any of the four tests results, in isolation, until more extensive testing against gold standards is done.
We recently evaluated the performance of the HSV-1 versions of these commercial assays for detecting HSV-1 antibodies [18] , an infection of very high seroprevalence in MENA [24, 41] , unlike that of HSV-2 [19, 25] . Notably, the assays showed excellent agreement with one another and in all comparison metrics for detecting HSV-1 antibodies [18] , unlike the case for detecting HSV-2 antibodies (Tables 1  and 2 ). This further highlights the need for cautious interpretation of HSV-2 serology measures in particular, and in all global populations. This study has limitations. First, we treated HerpeSelect ® IB and Euroline-WB as reference standards, because of their unique test formats, but could not use, for cost and logistical reasons, one of several widely recognized reference standards such as the UW-WB [12] , the immunodot enzyme assay [42] [43] [44] , or the monoclonal antibody inhibition test used in the United Kingdom [12] . Next, HSV-2 seroprevalence was low (about 5%), as it is low in MENA populations [19, 25] , but such low seroprevalence resulted in wide confidence intervals for several of the comparison metrics, as most metrics, such as Cohen's kappa statistic, depend on infection seroprevalence [45] . Furthermore, it is difficult to determine whether observed results are due to regionally-specific factors, the small number of positive samples, the differences in performance of the kits, or the reference standards selected. However, given existing evidence that shows significant variations in the sensitivities in HSV-2 serology testing across different diagnostics [13] [14] [15] [16] , we are inclined to believe that this could be the main cause of the differences between the assays. To clarify this better in future research, larger sample sizes should be used in consideration of the low HSV-2 seroprevalence. Further, we used existing sera from other studies [20] [21] [22] [23] , which was collected from men, thus preventing us from assessing sex-based differences in assay performance-of note that women have a higher seroprevalence than men, because of higher biological susceptibility [3, 39] . Finally, though our sample included populations from ten different MENA nationalities to be broadly representative of MENA populations, we did not have specimens from all of the 23 different MENA nationalities.
In conclusion, performance of four common commercial assays in detecting HSV-2 antibodies was analyzed in a composite sample of ten MENA national populations, to inform design of epidemiological studies for HSV-2 infection. The four assays demonstrated excellent negative and overall concordance with each other. The two ELISA kits were also comparable in their diagnostic performance when compared to the IB/WB assays. However, positive concordance between the assays was imperfect, leading to a fair to good Cohen's kappa statistic. Development and use of multiple test algorithms may provide the most accurate test results for HSV-2 in MENA populations, to optimize sensitivity and specificity. Meanwhile, these findings suggest caution in future use of these assays, alone, for HSV-2 antibody detection, in both epidemiologic scientific studies and clinical settings.
